| |
TNF-α inhibitors (n = 28)
|
IL-6R inhibitor (n = 32)
|
csDMARDs alone (n = 12)
|
HC (n = 20)
|
|---|
|
Mean age (years)
|
56.7 ± 12.1
|
55.5 ± 14.1
|
58.1 ± 14.3
|
53.3 ± 11.4
|
|
Female (%)
|
22 (78.6%)
|
24 (75.0%)
|
10 (83.3%)
|
15 (75.0%)
|
|
RF positivity (%)
|
22 (78.6%)
|
20 (62.5%)
|
8 (66.7%)
|
NA
|
|
ACPA positivity (%)
|
19 (67.9%)
|
18 (56.3%)
|
7 (58.3%)
|
NA
|
|
ESR (mm/first hour)
|
44.4 ± 30.0*
|
35.8 ± 21.8
|
30.5 ± 22.6
|
NA
|
|
CRP (mg/dl)
|
2.3 ± 2.5*
|
2.0 ± 2.3
|
1.3 ± 1.4
|
NA
|
|
DAS28 at baseline
|
5.89 ± 0.59*
|
5.95 ± 0.70*
|
4.80 ± 0.71
|
NA
|
|
Daily steroid dose (mg)
|
6.3 ± 1.6
|
6.5 ± 1.5
|
5.6 ± 1.9
|
NA
|
|
Baseline csDMARDs
|
|
MTX + SSZ + HCQ
|
23 (82.1%)
|
26 (81.3%)
|
10 (83.4%)
|
NA
|
|
SSZ + HCQ + Cyc
|
2 (7.1%)
|
3 (9.4%)
|
1 (8.3%)
|
NA
|
|
MTX + SSZ
|
1 (3.6%)
|
1 (3.1%)
|
0 (0.0%)
|
NA
|
|
MTX + SSZ + Cyc
|
1 (3.6%)
|
0 (0.0%)
|
1 (8.3%)
|
NA
|
|
MTX+ SSZ + HCQ + Cyc
|
1 (3.6%)
|
2 (6.2%)
|
0 (0.0%)
|
NA
|
- Abbreviations: ACPA Anticitrullinated peptide antibodies, CRP C-reactive protein, csDMARDs Conventional synthetic disease-modifying antirheumatic drugs, Cyc Cyclosporine, DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate, HCQ Hydroxychloroquine, IL-6R Interleukin-6 receptor, MTX Methotrexate, NA Not applicable, RF Rheumatoid factor, SSZ Sulfasalazine, TNF-α Tumor necrosis factor-α
- Data are presented as mean ± SD, number (percent), or median (25th–75th quartiles)
- *p < 0.05 vs. HC by Mann-Whitney U test for between-group comparison of numerical variables
